Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2010
Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia.
Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 6 syntheses or guidelines pooled it, 177 citations in OpenAlex.
- Switching antipsychotics versus continued current treatment in people with non-responsive schizophrenia.The Cochrane database of systematic reviews · 2025Pooled it
- Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.Psychopharmacology · 2019Pooled it
- Predictive Factors of Treatment Resistance in First Episode of Psychosis: A Systematic Review.Frontiers in psychiatry · 2019Pooled it
- Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia.The Cochrane database of systematic reviews · 2018Pooled it
- Is the PANSS used correctly? a systematic review.BMC psychiatry · 2011Pooled it
- Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia.BMC psychiatry · 2011Pooled it
- Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.Current neuropharmacology · 2023Trial
- Changing the Antipsychotic in Early Nonimprovers to Amisulpride or Olanzapine: Randomized, Double-Blind Trial in Patients With Schizophrenia.Schizophrenia bulletin · 2022Trial
- Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study.Journal of child and adolescent psychopharmacology · 2021Trial
- Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics.BMC psychiatry · 2018Trial
- A Pilot Study of the Usefulness of a Single Olanzapine Plasma Concentration as an Indicator of Early Drug Effect in a Small Sample of First-Episode Psychosis Patients.Journal of clinical psychopharmacology · 2017Trial
- The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis.The pharmacogenomics journal · 2017Trial
- Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial.European child & adolescent psychiatry · 2015Trial
- Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation.BMC psychiatry · 2015Trial
- Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population.The Journal of clinical psychiatry · 2015Trial
- Does lack of improvement in the first two weeks predict treatment resistance in recent-onset psychosis?Clinics (Sao Paulo, Brazil) · 2012Trial
- Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial.BMC medical research methodology · 2012Trial
- The relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from a randomized clinical trial.BMC psychiatry · 2011Trial
- Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months?The Journal of clinical psychiatry · 2011Trial
- Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia.BMC psychiatry · 2011Trial
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Our objective was to prospectively assess whether early (ie, 2 weeks) response to an antipsychotic predicts later (12-week) response and whether 'switching' early non-responders to another antipsychotic is a better strategy than 'staying'. This randomized, double-blind, flexible-dosed, 12-week study enrolled 628 patients diagnosed with schizophrenia or schizoaffective disorder. All initiated treatment with risperidone. Early response was defined as > or =20% improvement on the Positive and Negative Syndrome Scale (PANSS) total score following 2 weeks of treatment. Early responders (ERs) continued on risperidone, whereas early non-responders (ENRs) were randomized (1 : 1) to continue on risperidone 2-6 mg/day or switch to olanzapine 10-20 mg/day for 10 additional weeks. Compared with ENRs, risperidone ERs showed significantly greater reduction in PANSS total score (end point; p<001). Early response/non-response was highly predictive of subsequent clinical outcomes. Switching risperidone ENRs to olanzapine at week 2 resulted in a small but significantly greater reduction in PANSS total score (end point; p=0.020) and in depressive symptoms (end point; p=0.004); the reduction in PANSS was greater among those who were still moderately ill at 2 weeks. Switching risperidone ENRs to olanzapine also resulted in significantly greater increases in triglycerides, a significantly greater decrease in prolactin, and significantly less treatment-emergent dyskinesia. This is the first study to prospectively show that early response/non-response to an antipsychotic (risperidone) is a reliable clinical marker of subsequent clinical outcomes and that a 'switching' strategy based on this information may lead to greater clinical improvement than staying on a drug for a longer period in some patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.